anti-CI135 CAR-T vs Gilteritinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: FLT3 · full Acute Myeloid Leukemia pipeline
anti-CI135 CAR-T
Developed by Hrain Biotechnology Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Gilteritinib
Marketed by Astellas Pharma
NCT02997202 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 178 participants per group and a hard clinical primary endpoint of relapse-free survival. The primary endpoint was not statistically significant (hazard ratio 0.679; p=0.0518), so the results provide well-controlled but inconclusive evidence of benefit.
Next expected readout: December 2026 · NCT06001788 (registry estimate)
Reported efficacy
Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) (missed)
Result source: NCT02752035
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | anti-CI135 CAR-T | Gilteritinib |
|---|---|---|
| OS, median | —Not reported | 9.8 vs 9.2vs AZANCT027520353 other results
|
| Complete remission | —Not reported | 21.1% vs 10.5%vs Salvage ChemotherapyNCT024219394 other results
|
| Event-free survival, median | —Not reported | 0.0 vs 0.0vs AZANCT027520355 other results
|
| Duration of response, median | —Not reported | 14.8 vs 1.8vs Salvage ChemotherapyNCT02421939 |
OS, median
- anti-CI135 CAR-T
- —Not reported
- Gilteritinib
- 9.8 vs 9.2vs AZANCT02752035
3 other results
- 9.3 vs 5.6 NCT02421939
- 5.2 vs 9.2 NCT02752035
- 5.8 NCT03730012
Complete remission
- anti-CI135 CAR-T
- —Not reported
- Gilteritinib
- 21.1% vs 10.5%vs Salvage ChemotherapyNCT02421939
4 other results
- 25.8% vs 17.5% NCT02752035
- 9.1% vs 17.5% NCT02752035
- 33.3% NCT03730012
- 0% NCT03730012
Event-free survival, median
- anti-CI135 CAR-T
- —Not reported
- Gilteritinib
- 0.0 vs 0.0vs AZANCT02752035
5 other results
- 2.8 vs 0.7 NCT02421939
- 0.0 vs 0.0 NCT02752035
- 14.1 vs 6.7 NCT02927262
- 5.8 NCT03730012
- 1.7 NCT03730012
Duration of response, median
- anti-CI135 CAR-T
- —Not reported
- Gilteritinib
- 14.8 vs 1.8vs Salvage ChemotherapyNCT02421939
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
anti-CI135 CAR-T: no structured comparison results are available for Acute Myeloid Leukemia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. anti-CI135 CAR-T: 0 of 4 rows · Gilteritinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Gilteritinib |
|---|---|
| Dropout rate | 31.5%a NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results—Randomized Cohort: Gilteritinib NCT02752035 · Phase 3 · monotherapy —Randomized Cohort: Gilteritinib + NCT02752035 · Phase 3 · combination n/a: no completion milestoneSafety Cohort: Gilteritinib + Azac NCT02752035 · Phase 3 · combination 100% NCT02421939 · Phase 3 61.9% NCT02927262 · Phase 2 · registry result, not featured evidence n/a: no completion milestone120 mg + 420 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone120 mg + 840 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 100%200 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 100%120 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 66.7%80 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 100%40 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence —450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results—Randomized Cohort: Gilteritinib NCT02752035 · Phase 3 · monotherapy —Randomized Cohort: Gilteritinib + NCT02752035 · Phase 3 · combination 6.7%Safety Cohort: Gilteritinib + Azac NCT02752035 · Phase 3 · combination 13% NCT02421939 · Phase 3 11.1% NCT02927262 · Phase 2 · registry result, not featured evidence 0%120 mg + 420 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 12.5%120 mg + 840 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination —200 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence —450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 17.6%300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 25%200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 20.6%200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 7.2%120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 9.5%80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 13.3%40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 51.7%a NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results90.9%Randomized Cohort: Gilteritinib NCT02752035 · Phase 3 · monotherapy 92%Randomized Cohort: Gilteritinib + NCT02752035 · Phase 3 · combination 93.3%Safety Cohort: Gilteritinib + Azac NCT02752035 · Phase 3 · combination 85.8% NCT02421939 · Phase 3 38.7% NCT02927262 · Phase 2 · registry result, not featured evidence 100%120 mg + 420 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 87.5%120 mg + 840 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 0%200 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 66.7%120 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 33.3%80 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 100%40 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 66.7%450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 66.7%300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 82.4%300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 66.7%200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 92%200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 33.3%120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 78.8%120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 66.7%80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 90.5%80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 66.7%40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 92.3%40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 40%20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 66.7%20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | a chronic graft versus host disease 52.8% (placebo 43.5%) acute graft versus host disease 37.6% (placebo 36.2%) neutrophil count decreased 27.5% (placebo 9.6%) NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 24 more resultsanaemia 45.5% alanine aminotransferase increased 40.7% aspartate aminotransferase increased 39.4% NCT02421939 · Phase 3 blood creatine phosphokinase increased 29% (placebo 2.9%) neutrophil count decreased 19.4% (placebo 8.6%) platelet count decreased 19.4% (placebo 11.4%) NCT02927262 · Phase 2 · registry result, not featured evidence 120 mg + 420 mg decreased appetite 100% dizziness 100% dyspnoea 100% NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 120 mg + 840 mg diarrhoea 50% fatigue 50% nausea 50% NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 200 mg benign breast neoplasm 100% cough 100% covid-19 100% NCT02561455 · Phase 1/2 · registry result, not featured evidence 120 mg cough 66.7% decreased appetite 66.7% diarrhoea 66.7% NCT02561455 · Phase 1/2 · registry result, not featured evidence 80 mg anorectal discomfort 33.3% anxiety 33.3% arthralgia 33.3% NCT02561455 · Phase 1/2 · registry result, not featured evidence 40 mg cough 100% muscle spasms 100% abdominal discomfort 50% NCT02561455 · Phase 1/2 · registry result, not featured evidence 450 mg aspartate aminotransferase increased 66.7% hyperglycaemia 66.7% abdominal pain 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 300 mg pollakiuria 66.7% alanine aminotransferase increased 33.3% anaemia 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 300 mg anaemia 35.3% diarrhoea 29.4% epistaxis 23.5% NCT02014558 · Phase 1/2 · registry result, not featured evidence 200 mg fatigue 100% abdominal pain 33.3% aspartate aminotransferase increased 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 200 mg diarrhoea 45% aspartate aminotransferase increased 35% anaemia 33% NCT02014558 · Phase 1/2 · registry result, not featured evidence 120 mg constipation 66.7% abdominal pain lower 33.3% blood bilirubin increased 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 120 mg anaemia 40.9% diarrhoea 40.9% fatigue 40.9% NCT02014558 · Phase 1/2 · registry result, not featured evidence 80 mg decreased appetite 66.7% nausea 66.7% vomiting 66.7% NCT02014558 · Phase 1/2 · registry result, not featured evidence 80 mg fatigue 38.1% anaemia 33.3% cough 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 40 mg constipation 33.3% dizziness 33.3% dry skin 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 40 mg dyspnoea 38.5% fatigue 38.5% anaemia 30.8% NCT02014558 · Phase 1/2 · registry result, not featured evidence 20 mg anaemia 40% nausea 40% abdominal pain 20% NCT02014558 · Phase 1/2 · registry result, not featured evidence 20 mg hypokalaemia 41.7% fatigue 33.3% oedema peripheral 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 37 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Gilteritinib
show 1 more result
show 4 more results
show 4 more results
show 1 more result
show 1 more result
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 34 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: anti-CI135 CAR-T's landscape · Gilteritinib's landscape